HUP0101017A3 - Compositions and methods for systemic delivery of oral vaccines and therapeutic agents - Google Patents

Compositions and methods for systemic delivery of oral vaccines and therapeutic agents

Info

Publication number
HUP0101017A3
HUP0101017A3 HU0101017A HUP0101017A HUP0101017A3 HU P0101017 A3 HUP0101017 A3 HU P0101017A3 HU 0101017 A HU0101017 A HU 0101017A HU P0101017 A HUP0101017 A HU P0101017A HU P0101017 A3 HUP0101017 A3 HU P0101017A3
Authority
HU
Hungary
Prior art keywords
compositions
methods
therapeutic agents
systemic delivery
oral vaccines
Prior art date
Application number
HU0101017A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Thomas Jefferson University Ph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University Ph filed Critical Thomas Jefferson University Ph
Publication of HUP0101017A2 publication Critical patent/HUP0101017A2/hu
Publication of HUP0101017A3 publication Critical patent/HUP0101017A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/832Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0101017A 1997-10-20 1998-10-16 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents HUP0101017A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/954,302 US6051239A (en) 1997-10-20 1997-10-20 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
PCT/US1998/021897 WO1999020306A1 (en) 1997-10-20 1998-10-16 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents

Publications (2)

Publication Number Publication Date
HUP0101017A2 HUP0101017A2 (hu) 2001-07-30
HUP0101017A3 true HUP0101017A3 (en) 2003-11-28

Family

ID=25495232

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101017A HUP0101017A3 (en) 1997-10-20 1998-10-16 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents

Country Status (16)

Country Link
US (1) US6051239A (enExample)
EP (1) EP1024827B1 (enExample)
JP (1) JP2001522783A (enExample)
KR (1) KR100594787B1 (enExample)
CN (1) CN1246038C (enExample)
AT (1) ATE355076T1 (enExample)
AU (1) AU756475B2 (enExample)
BR (1) BR9815255A (enExample)
CA (1) CA2306995A1 (enExample)
DE (1) DE69837209T2 (enExample)
EE (1) EE200000536A (enExample)
HU (1) HUP0101017A3 (enExample)
IL (1) IL135743A (enExample)
NZ (1) NZ504549A (enExample)
RU (1) RU2227042C2 (enExample)
WO (1) WO1999020306A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227010B2 (en) 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
KR100753765B1 (ko) * 2000-02-08 2007-08-31 알레간 인코포레이티드 보툴리눔 독소 약제학적 조성물
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
AU2002228887B2 (en) * 2000-11-06 2006-08-24 United States Army Medical Research And Material Command Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
AU2003237346A1 (en) * 2002-05-31 2003-12-19 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
EP1629090B1 (en) * 2002-11-06 2014-03-05 iBio, Inc. Expression of foreign sequences in plants using trans-activation system
US7491509B2 (en) 2003-02-03 2009-02-17 Fraunhofer Usa, Inc. System for expression of genes in plants
US7683238B2 (en) * 2002-11-12 2010-03-23 iBio, Inc. and Fraunhofer USA, Inc. Production of pharmaceutically active proteins in sprouted seedlings
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
AU2003300666A1 (en) * 2002-12-20 2004-07-29 Botulinum Toxin Research Associates, Inc. Pharmaceutical botulinum toxin compositions
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
AU2005216133A1 (en) * 2004-02-20 2005-09-09 Fraunhofer Usa, Inc. Systems and methods for clonal expression in plants
US7306807B2 (en) 2004-09-13 2007-12-11 Wyeth Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease
US7785606B2 (en) * 2004-11-22 2010-08-31 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
JP4667507B2 (ja) 2005-10-07 2011-04-13 ファイザー・プロダクツ・インク イヌインフルエンザを治療するワクチンおよび方法
EP1931379B1 (en) 2005-10-07 2013-05-29 Health Protection Agency Proteins with improved solubility and methods for producing and using same
US20080299149A1 (en) * 2007-05-30 2008-12-04 Wyeth Raccoon Poxvirus Expressing Genes of Feline Antigens
US8445650B2 (en) * 2007-09-25 2013-05-21 Thomas Jefferson University Mutant botulinum neurotoxin serotype A polypeptide and uses thereof
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
EP2948174B1 (en) 2013-01-28 2019-09-11 New York University Treatment methods using atoxic neurotoxin derivatives
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
EP3230457B1 (en) 2014-12-09 2021-06-30 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
BR112020012641A2 (pt) 2017-12-20 2020-12-01 Allergan, Inc. polipeptídeos de domínio de ligação celular de toxina de botulinum e métodos de uso para rejuvenescimento da pele

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
AU695623B2 (en) * 1994-05-31 1998-08-20 Allergan, Inc. Modification of clostridial toxins for use as transport proteins
EP0796326A4 (en) * 1994-10-24 2000-01-19 Ophidian Pharm Inc VACCINE AND ANTITOXIN FOR THE TREATMENT AND PREVENTION OF C. DIFFICILE DISEASE
WO1996040229A1 (en) * 1995-06-07 1996-12-19 Thomas Jefferson University Vaccines synthesized by transgenic plants
WO1997032599A1 (en) * 1996-03-08 1997-09-12 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties

Also Published As

Publication number Publication date
DE69837209T2 (de) 2007-10-31
HUP0101017A2 (hu) 2001-07-30
EP1024827B1 (en) 2007-02-28
IL135743A (en) 2004-03-28
CN1290174A (zh) 2001-04-04
WO1999020306A1 (en) 1999-04-29
BR9815255A (pt) 2001-12-26
DE69837209D1 (de) 2007-04-12
US6051239A (en) 2000-04-18
EP1024827A4 (en) 2002-08-28
EE200000536A (et) 2002-04-15
IL135743A0 (en) 2001-05-20
ATE355076T1 (de) 2006-03-15
EP1024827A1 (en) 2000-08-09
JP2001522783A (ja) 2001-11-20
AU756475B2 (en) 2003-01-16
CN1246038C (zh) 2006-03-22
RU2227042C2 (ru) 2004-04-20
CA2306995A1 (en) 1999-04-29
KR20010031236A (ko) 2001-04-16
NZ504549A (en) 2002-12-20
KR100594787B1 (ko) 2006-07-03
AU1094799A (en) 1999-05-10

Similar Documents

Publication Publication Date Title
HUP0101017A3 (en) Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
ZA968907B (en) Compositions and methods for buccal delivery of pharmaceutical agents
IL136488A0 (en) Transdermal delivery of particulate vaccine compositions
EP1165048A4 (en) COMPOSITIONS AND METHOD FOR IMPROVED ADMINISTRATION OF IONIZABLE HYDROPHOLE THERAPEUTIC SUBSTANCES
IL123106A0 (en) Conjugation-stabilized therapeutic agent compositions delivery and diagnostic formulations
ZA942804B (en) Oral drug delivery compositions and methods
IL127189A0 (en) Compositions methods and devices for the transdermal delivery of drugs
EG24044A (en) pharmaceutical formulation of omeprazole
HUP0004802A3 (en) Nicotine compositions and methods of formulation thereof
ZA982609B (en) Pharmaceutical composition for the oral administration of an n-piperidinopyrazole-e-carboxamide derivative its salts and their solvates
AU4425496A (en) Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
IL131201A0 (en) Pharmaceutical formulations comprising amoxocyllin and clavulanate
PL330814A1 (en) Compounds for and methods of delivering pharmaceutical preparations and their application
AUPO727097A0 (en) Method of treatment of hepatoma and pharmaceutical compositions for use therein
HUP0004096A3 (en) Aggregates of human insulin derivatives and pharmaceutical compositions comprising thereof
IL133053A0 (en) Local delivery of long lasting therapeutic agents
HUP0202862A3 (en) Pharmaceutical composition containing novel combination of loteprednol and antihistamines
EP1036573A4 (en) DEVICE FOR ADMINISTERING A SUBSTANCE THROUGH THE SKIN OR A MUCUTINE
EP1181022A4 (en) MEDICAL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
HUP0002683A3 (en) Compositions and methods for enhancing delivery of therapeutic agents to cells
GB9710800D0 (en) Pharmaceutical composition and method of preparing it
HUP9800573A3 (en) Rapamycin formulations for oral administration and process for their preparation
IL134958A0 (en) Serotonin containing formulation for oral administration and method of use
AU3937693A (en) Methods and compositions for oral delivery of therapeutic agents
HUP0201667A3 (en) Oral form of administration